Evaluation of ceftazidime-avibactam resistance in clinical isolates of Enterobacterales from a large tertiary-care hospital, Italy, 2019-2023

Evaluation of ceftazidime-avibactam resistance in clinical isolates of Enterobacterales from a large tertiary-care hospital, Italy, 2019-2023

Not available.

Saved in:

Bibliographic Details
Main Authors:	L. Calabrese, E. Willison, G. Codda, E. Costa, V. Di Pilato, A. Marchese
Format:	Article
Language:	English
Published:	PAGEPress Publications 2024-12-01
Series:	Microbiologia Medica
Online Access:	https://www.pagepressjournals.org/mm/article/view/13227
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections
by: Luca Mezzadri, et al.
Published: (2024-12-01)

Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area
by: Şevval Arduç Tok, et al.
Published: (2024-12-01)

In vitro activity of ceftazidime-avibactam in combination with aztreonam against carbapenem resistant Enterobacterales isolated from intensive care units
by: Aya Bedawy, et al.
Published: (2024-11-01)

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
by: Sunali, et al.
Published: (2025-01-01)

The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
by: Shobana Selvaganesan, et al.
Published: (2024-12-01)

Ceftolozane-tazobactam, ceftazidime-avibactam and ceftazidime-avibactam plus aztreonam combination: Upcoming hope for hospital-acquired MDR/XDR Pseudomonas aeruginosa infections
by: Asmaa Elbrolosy, et al.
Published: (2024-05-01)

Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae
by: Yitan Li, et al.
Published: (2024-12-01)

Safety and Efficacy of Ceftazidime/Avibactam in the Treatment of Severe Neonatal Infections
by: Mi Zhou, et al.
Published: (2024-12-01)

Ceftazidime-avibactam susceptibility against Escherichia coli and Klebsiella pneumoniae
by: Arun Sachu, et al.
Published: (2025-02-01)

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected in Turkey and the Middle East: ATLAS Global Surveillance Program 2018-2022
by: Meredith Hackel, et al.
Published: (2024-12-01)

Ceftazidime-Avibactam versus Polymyxin-Based Therapies: A Study on 30-Day Mortality in Carbapenem-Resistant Enterobacterales Bloodstream Infections in an OXA-48 Endemic Region
by: Rıdvan Dumlu, et al.
Published: (2024-12-01)

Characterization of Metallo β-Lactamase Producing <i>Enterobacterales</i> Isolates with Susceptibility to the Aztreonam/Avibactam Combination
by: Brunella Posteraro, et al.
Published: (2024-12-01)

The In Vitro Synergistic And Antibiofilm Activity Of Ceftazidime/Avibactam Against Achromobacter Species Isolated From Cystic Fibrosis Patients
by: EMEL MATARACI KARA, et al.
Published: (2024-12-01)

Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021
by: Marya D. Zilberberg, et al.
Published: (2025-01-01)

Experimental prescription, rising resistance: the alarming misuse of ceftazidime-avibactam in healthcare systems
by: Mojtaba Akbari, et al.
Published: (2024-12-01)

Correction for Qiao et al., “A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae”
by: Sai Qiao, et al.
Published: (2024-12-01)

A Novel Variant of KPC-179 Conferring Ceftazidime-Avibactam Resistance in a Carbapenem-Resistant Klebsiella pneumoniae Isolate
by: Liao Q, et al.
Published: (2024-11-01)

<i>In vivo</i> emergence of cefiderocol resistance in <i>Pseudomonas aeruginosa</i> following prolonged treatment at San Martino Policlinico Hospital (HSM), Genoa, Italy
by: E. Costa, et al.
Published: (2024-12-01)

Susceptibility pattern of Ceftazidime-Avibactam against multi drug resistant gram-negative rods
by: Mehwish Sajjad mehmood, et al.
Published: (2024-12-01)

The Use of Ceftazidime–Avibactam in a Pediatric Intensive Care Unit—An Observational Prospective Study
by: Raquel García Romero, et al.
Published: (2024-11-01)

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales
by: Helio S. Sader, et al.
Published: (2024-11-01)

Contribution of efflux pump hyperactivity to the resistance to new β-lactam-β-lactamase inhibitor combinations including ceftazidime-avibactam, aztreonam-avibactam, and imipenem-relebactam
by: Sung Pin Tseng, et al.
Published: (2024-12-01)

Ceftazidime–avibactam for the Treatment of Intra-abdominal Sepsis and Urosepsis: A Retrospective Hospital-based Study in India
by: Prachee Sathe, et al.
Published: (2024-12-01)

Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy
by: Jim Abi Frem, et al.
Published: (2024-12-01)

Global phylogeography and genetic characterization of carbapenem and ceftazidime-avibactam resistant KPC-33-producing Pseudomonas aeruginosa
by: Longjie Zhou, et al.
Published: (2025-01-01)

Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
by: Louie Mar Gangcuangco, et al.
Published: (2016-01-01)

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study
by: Yu CH, et al.
Published: (2024-12-01)

A Multicenter Retrospective Study on Real-World Outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan
by: Tsung Ying Zegma Yang, et al.
Published: (2024-12-01)

In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis
by: Siquan Shen, et al.
Published: (2024-12-01)

Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022
by: Xi Li, et al.
Published: (2024-12-01)

Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin
by: Jingli Lu, et al.
Published: (2025-01-01)

Integral genomic description of blaNDM-5-harbouring plasmids recovered from Enterobacterales in Argentina.
by: Francisco González-Espinosa, et al.
Published: (2024-12-01)

Effectiveness of ceftazidime/avibactam as a continuous infusion in critically ill patients with OXA-48-producing Klebsiella pneumoniae infection
by: Ivan Šitum, et al.
Published: (2024-06-01)

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01)

Phenotypic detection of carbapenem-resistant Enterobacterales in clinical isolates at a tertiary care hospital
by: Astha Sinha, et al.
Published: (2024-01-01)

An Assessment Of Cefiderocol's Synergistic Effects With Eravacycline, Colistin, Meropenem, Levofloxacin, Ceftazidime/Avibactam, And Tobramycin Against Carbapenem-Resistant Pseudomonas Aeruginosa
by: Bekir Özer, et al.
Published: (2024-12-01)

Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae
by: Qingyu Shi, et al.
Published: (2024-12-01)

Overexpression of blaSHV-12 caused by tandem amplification contributed to ceftazidime/avibactam resistance in hypervirulent and carbapenem-resistant Klebsiella pneumoniae
by: Chao Liu, et al.
Published: (2024-12-01)

Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study
by: Thamer A. Almangour, et al.
Published: (2025-01-01)

Susceptibility of Enterobacterales Collected in the Middle East and Turkey to Aztreonam/Avibactam and Comparator Agents Stratified by Infection Source: ATLAS Surveillance Program 2018-2022
by: Mark Wise, et al.
Published: (2024-12-01)